Skip to content

Versigent VGNT Business Segments — SG&A

Similar metrics at other companies

Eos Energy Enterprises, Inc. logo
EOSEReportable Segment — SG&A
$24.1M+14.8%
ITG
ITGRReportable Segment — SG&A
$52.94M+14.3%
Tarsus Pharmaceuticals, Inc. logo
TARSReportable Segment — SG&A
$51.95M+110%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — SG&A
$80.25M+32.8%
Indivior Pharmaceuticals, Inc.
 logo
INDVReportable Segment — SG&A
$124M-6.8%
BioCryst Pharmaceuticals logo
BCRXReportable Segment — SG&A
$42.95M-9.9%

Other financials

Income statement

See full
Revenue$2.2B+9.3%
Gross profit$244.0M-2.0%
Operating income$74.0M-39.8%
Net income$78.0M-17.9%

Balance sheet

See full
Cash & equivalents$282.0M
Total debt$2.4B
Total equity-$48.0M-103%
Total assets$4.9B

Cash flow

See full
Operating cash flow$36.0M-10.0%
CapEx$66.0M+78.4%
Free cash flow-$30.0M-1,100%

Valuation

See full
Market cap$3.03B

Returns & leverage

See full
Debt / equity0.2×
Current ratio1.4×

Where this comes from

Reported directly by Versigent in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Versigent ’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Versigent 's business segments — sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Versigent 's business segments — SG&A?
Versigent (VGNT) reported business segments — SG&A of $97M in Q1 2026.
What does business segments — SG&A mean?
This metric reflects the operating expenses incurred by a specific business segment that are not directly tied to production, such as marketing, sales commissions, and administrative overhead. It provides insight into the segment's operational leverage and the cost of maintaining its business infrastructure. Investors use this to evaluate how effectively the segment manages its discretionary spending relative to its revenue growth.